A 1 year follow-up study to the G304 study to demonstrate the efficacy of the Grass MATA MPL (0.5 mL)

Trial Profile

A 1 year follow-up study to the G304 study to demonstrate the efficacy of the Grass MATA MPL (0.5 mL)

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
  • Indications Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 09 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top